Synopsis
Synopsis
0
JDMF
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 67555, R
2. Alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2h-1-benzopyran-2-methanol
3. Bystolic
4. Hydrochloride, Nebivolol
5. Lobivon
6. Nebilet
7. Nebivolol
8. R 67555
9. R-67555
10. R67555
11. Silostar
1. 169293-50-9
2. Nebivolol Hcl
3. 2,2'-azanediylbis(1-(6-fluorochroman-2-yl)ethanol) Hydrochloride
4. 152520-56-4
5. Rac Nebivolol Hydrochloride
6. R 065824 Hydrochloride
7. Nebilox
8. Rac-nebivolol Hcl
9. R-067555
10. Schembl514784
11. N-phenyliminodiaceticacid
12. Chembl1201731
13. Akos016006035
14. Ac-4233
15. Ac-5636
16. Ccg-214847
17. Ro67555
18. As-12100
19. Cs-0362720
20. Ft-0652243
21. Ft-0655833
22. 520n564
23. W-60374
24. J-010524
25. 1-(6-fluoro-3,4-dihydro-2h-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2h-chromen-2-yl)-2-hydroxyethyl]amino]ethanol;hydrochloride
26. 2h-1-benzopyran-2-methanol,a,a'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-,hydrochloride(1:1)
27. Alpha,alpha'[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2h-1-benzopyran-2-methanol]hydrochloride
| Molecular Weight | 441.9 g/mol |
|---|---|
| Molecular Formula | C22H26ClF2NO4 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 6 |
| Exact Mass | 441.1518423 g/mol |
| Monoisotopic Mass | 441.1518423 g/mol |
| Topological Polar Surface Area | 71 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 483 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 4 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Adrenergic beta-1 Receptor Agonists
Compounds that bind to and activate ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Agonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Rampex Labs – Simplifying Synthesis with Innovation, Quality, and Commitment to Global Pharmaceutical Excellence.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-01-05
Pay. Date : 2014-10-07
DMF Number : 28627
Submission : 2014-09-10
Status : Active
Type : II
Date of Issue : 2025-09-03
Valid Till : 2028-09-02
Written Confirmation Number : WC-0362
Address of the Firm :
NDC Package Code : 69037-0004
Start Marketing Date : 2007-12-17
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30052
Submission : 2015-12-03
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35332
Submission : 2021-10-28
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : Complete
Rev. Date : 2015-01-05
Pay. Date : 2014-10-07
DMF Number : 28627
Submission : 2014-09-10
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-03-25
Pay. Date : 2013-09-11
DMF Number : 21152
Submission : 2007-12-08
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2014-10-13
Pay. Date : 2014-10-06
DMF Number : 22735
Submission : 2009-03-31
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-04-04
Pay. Date : 2012-12-05
DMF Number : 25296
Submission : 2011-09-12
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15417
Submission : 2001-05-07
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2016-10-21
Pay. Date : 2016-08-24
DMF Number : 29996
Submission : 2016-02-19
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2014-12-01
Pay. Date : 2014-11-20
DMF Number : 24916
Submission : 2011-05-04
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26343
Submission : 2012-08-21
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22906
Submission : 2009-06-29
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2016-04-13
Pay. Date : 2015-09-21
DMF Number : 29730
Submission : 2015-09-28
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Certificate Number : CEP 2024-481 - Rev 00
Status : Valid
Issue Date : 2025-12-04
Type : Chemical
Substance Number : 2775

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2022-095 - Rev 00
Status : Valid
Issue Date : 2022-08-31
Type : Chemical
Substance Number : 2775

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Nebivolol Hydrochloride, Micronised
Certificate Number : CEP 2024-214 - Rev 00
Status : Valid
Issue Date : 2025-04-25
Type : Chemical
Substance Number : 2775

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2021-403 - Rev 02
Status : Valid
Issue Date : 2026-04-10
Type : Chemical
Substance Number : 2775

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2023-063 - Rev 02
Status : Valid
Issue Date : 2026-03-17
Type : Chemical
Substance Number : 2775

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2024-172 - Rev 00
Status : Valid
Issue Date : 2025-09-04
Type : Chemical
Substance Number : 2775

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Nebivolol Hydrochloride, Crystalline, Micronised...
Certificate Number : CEP 2022-193 - Rev 02
Status : Valid
Issue Date : 2025-04-14
Type : Chemical
Substance Number : 2775

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2022-069 - Rev 00
Status : Valid
Issue Date : 2024-04-25
Type : Chemical
Substance Number : 2775

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2023-122 - Rev 01
Status : Valid
Issue Date : 2025-05-05
Type : Chemical
Substance Number : 2775

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2022-170 - Rev 00
Status : Valid
Issue Date : 2022-12-09
Type : Chemical
Substance Number : 2775

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
Date of Issue : 2025-09-03
Valid Till : 2028-09-02
Written Confirmation Number : WC-0362
Address of the Firm : Plot No:4, Hetero Infrastructure SEZ Ltd.,Narasapuram, Visakhapatnam-531081, And...
Date of Issue : 2022-11-18
Valid Till : 2025-02-18
Written Confirmation Number : WC-0325
Address of the Firm : M/s. Abhilasha Pharma Pvt. Ltd, Plot No. 1408/1409, G.I.D.C, Near Buch Plastic U...

Date of Issue : 2025-09-29
Valid Till : 2028-06-05
Written Confirmation Number : WC-0370
Address of the Firm : Plot No. 288/A, 289-290, G.I.D.C At & Post-Ankleshwar, Dist.- Bharuch, Gujarat, ...

Date of Issue : 2025-09-03
Valid Till : 2028-09-02
Written Confirmation Number : WC-0074
Address of the Firm : 294, G.I.D.C. Estate, Ankleshwar, Dist. -Bharuch-393002, Gujarat State, India

Date of Issue : 2025-09-19
Valid Till : 2028-07-03
Written Confirmation Number : WC-0040
Address of the Firm : Unit-l, Sy. No. 213, 214 & 255, Bonthapally (Village),Gummadidala (Mandal), Sang...

Nebivolol Hydrochloride IH/Ph. Eur
Date of Issue : 2025-09-08
Valid Till : 2028-08-15
Written Confirmation Number : WC-0022
Address of the Firm : Plot No. 182 to 186, 192-A and 193 to 197 & 212/A,B,C,D Phase-ll, IDA, Pashamyla...

Nebivolol Hydrochloride Ph. Eur.
Date of Issue : 2025-09-11
Valid Till : 2028-09-10
Written Confirmation Number : WC-0166
Address of the Firm : Indrad :382721, Tal. -Kadi, District: Mehsana, Gujarat, India

Date of Issue : 2021-02-12
Valid Till : 2022-07-04
Written Confirmation Number : WC-0070Amended
Address of the Firm : Unit-1, 37/A, 38, 39 A&B, PHASE-1, IDA, Jeedimetla, Hyderabad, 500 055, Telangan...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Huseong Bio Co., Ltd.
Registration Date : 2026-03-12
Registration Number : 20260312-178-I-747-07
Manufacturer Name : Alkem Laboratories Limited
Manufacturer Address : Plot No. 288/A, 289-290, GIDC, At & Post-Ankleshwar, Dist.-Bharuch, PIN 393002, Gujar...

Registrant Name : Hyundai Pharmaceutical Co., Ltd.
Registration Date : 2012-12-21
Registration Number : 20120413-178-I-94-02(2)
Manufacturer Name : Hetero Drugs Limited
Manufacturer Address : Sy.No.213.214&255, Bonthapally Village, Jinnaram Mandal, Medak District, Andhra, Prad...

Registrant Name : Youngjin Pharmaceutical Co., Ltd.
Registration Date : 2013-07-18
Registration Number : 20120413-178-I-94-02(3)
Manufacturer Name : Hetero Drugs Limited
Manufacturer Address : Sy.No.213.214&255, Bonthapally Village, Jinnaram Mandal, Medak District, Telangana, I...

Registrant Name : Korea Menarini Co., Ltd.
Registration Date : 2012-10-12
Registration Number : 20121012-178-I-128-03
Manufacturer Name : Janssen Pharmaceutica NV
Manufacturer Address : Jassen Pharmaceuticalaan 3 2440 Geel Belgium

Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2025-02-12
Registration Number : 20130412-178-I-198-05(A)
Manufacturer Name : Torrent Pharmaceuticals Ltd.
Manufacturer Address : Indrad-382 721, Tal:Kadi, City:Indrad, Dist.:Mehsana, Gujarat state, India

Registrant Name : Chodang Pharmaceutical Co., Ltd.
Registration Date : 2013-04-12
Registration Number : 20130412-178-I-198-05
Manufacturer Name : Torrent Pharmaceuticals Limi...
Manufacturer Address : Survey No 758, Indrad, Taluka Kadi, Ahmedabad - Mehsana Highway, District Mehsana. No...

Registrant Name : Sangjin Trading Co., Ltd.
Registration Date : 2013-02-14
Registration Number : 20130214-178-I-80-04
Manufacturer Name : Cadila Pharmaceuticals Ltd.
Manufacturer Address : 294, GIDC Estate., Ankleshwar - 393 002, Dist: Bharuch

Registrant Name : Korea Menarini Co., Ltd.
Registration Date : 2018-07-21
Registration Number : 20130214-178-I-80-04(4)
Manufacturer Name : Cadila Pharmaceuticals Ltd.
Manufacturer Address : 294, GIDC Estate., Ankleshwar - 393 002, Dist: Bharuch

Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2016-03-30
Registration Number : 20130214-178-I-80-04(1)
Manufacturer Name : Cadila Pharmaceuticals Ltd.
Manufacturer Address : 294, GIDC Estate, Ankleshwar-393 002, Dist: Bharuch

Registrant Name : Hiple Co., Ltd.
Registration Date : 2017-02-09
Registration Number : 20130214-178-I-80-04(2)
Manufacturer Name : Cadila Pharmaceuticals Ltd.
Manufacturer Address : 294, GIDC Estate., Ankleshwar - 393 002, Dist: Bharuch

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Details:
Testosterone Enanthate is a hormone drug, which is currently being evaluated in clinical studies for the treatment of undisclosed medical condition.
Lead Product(s): Testosterone Enanthate,Testosterone Cypionate,Testosterone Propionate,Testosterone,Methenolone Enanthate,Nandrolone Decanoate,Estradiol,Progesterone
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 06, 2026

Lead Product(s) : Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate, Testosterone, Methenolone Enanthate
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes
Details : Testosterone Enanthate is a hormone drug, which is currently being evaluated in clinical studies for the treatment of undisclosed medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
May 06, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Through the acquisition of Nebivolol HCl, targeting the Beta-2 adrenergic receptor, the deal aims to advance hypertension treatment.
Lead Product(s): Nebivolol,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Senores Pharmaceuticals
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Senores Pharmaceuticals
Deal Size : $1.6 million
Deal Type : Acquisition
Senores Pharmaceuticals Acquiring Apnar Pharma and Five ANDAs
Details : Through the acquisition of Nebivolol HCl, targeting the Beta-2 adrenergic receptor, the deal aims to advance hypertension treatment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Nebivolol,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nebivolol Tablets 5 mg Relative to Nebilet Tablets 5 mg
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Lead Product(s): Nebivolol,Ramipril
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 27, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Ramipril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 27, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Lead Product(s): Nebivolol,Amlodipine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 24, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 24, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Zofenopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Lead Product(s): Zofenopril,Nebivolol
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 25, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zofenopril,Nebivolol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zofenopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 25, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glaucoma, Open-Angle.
Lead Product(s): Nebivolol,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Trial Runners, LLC | Summit Analytical LLC
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 02, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Trial Runners, LLC | Summit Analytical LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glaucoma, Open-Angle.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
DWN12088 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Lead Product(s): DWN12088,Nebivolol
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 17, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DWN12088,Nebivolol
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DWN12088 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 17, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Nebivolol,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 07, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Nebivolol,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 07, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2018

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
14
PharmaCompass offers a list of Nebivolol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Nebivolol manufacturer or Nebivolol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nebivolol manufacturer or Nebivolol supplier.
A NEBIVOLOL HCI manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of NEBIVOLOL HCI, including repackagers and relabelers. The FDA regulates NEBIVOLOL HCI manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. NEBIVOLOL HCI API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of NEBIVOLOL HCI manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A NEBIVOLOL HCI supplier is an individual or a company that provides NEBIVOLOL HCI active pharmaceutical ingredient (API) or NEBIVOLOL HCI finished formulations upon request. The NEBIVOLOL HCI suppliers may include NEBIVOLOL HCI API manufacturers, exporters, distributors and traders.
click here to find a list of NEBIVOLOL HCI suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A NEBIVOLOL HCI DMF (Drug Master File) is a document detailing the whole manufacturing process of NEBIVOLOL HCI active pharmaceutical ingredient (API) in detail. Different forms of NEBIVOLOL HCI DMFs exist exist since differing nations have different regulations, such as NEBIVOLOL HCI USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A NEBIVOLOL HCI DMF submitted to regulatory agencies in the US is known as a USDMF. NEBIVOLOL HCI USDMF includes data on NEBIVOLOL HCI's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The NEBIVOLOL HCI USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of NEBIVOLOL HCI suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a NEBIVOLOL HCI Drug Master File in Korea (NEBIVOLOL HCI KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of NEBIVOLOL HCI. The MFDS reviews the NEBIVOLOL HCI KDMF as part of the drug registration process and uses the information provided in the NEBIVOLOL HCI KDMF to evaluate the safety and efficacy of the drug.
After submitting a NEBIVOLOL HCI KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their NEBIVOLOL HCI API can apply through the Korea Drug Master File (KDMF).
click here to find a list of NEBIVOLOL HCI suppliers with KDMF on PharmaCompass.
A NEBIVOLOL HCI CEP of the European Pharmacopoeia monograph is often referred to as a NEBIVOLOL HCI Certificate of Suitability (COS). The purpose of a NEBIVOLOL HCI CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of NEBIVOLOL HCI EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of NEBIVOLOL HCI to their clients by showing that a NEBIVOLOL HCI CEP has been issued for it. The manufacturer submits a NEBIVOLOL HCI CEP (COS) as part of the market authorization procedure, and it takes on the role of a NEBIVOLOL HCI CEP holder for the record. Additionally, the data presented in the NEBIVOLOL HCI CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the NEBIVOLOL HCI DMF.
A NEBIVOLOL HCI CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. NEBIVOLOL HCI CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of NEBIVOLOL HCI suppliers with CEP (COS) on PharmaCompass.
A NEBIVOLOL HCI written confirmation (NEBIVOLOL HCI WC) is an official document issued by a regulatory agency to a NEBIVOLOL HCI manufacturer, verifying that the manufacturing facility of a NEBIVOLOL HCI active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting NEBIVOLOL HCI APIs or NEBIVOLOL HCI finished pharmaceutical products to another nation, regulatory agencies frequently require a NEBIVOLOL HCI WC (written confirmation) as part of the regulatory process.
click here to find a list of NEBIVOLOL HCI suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing NEBIVOLOL HCI as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for NEBIVOLOL HCI API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture NEBIVOLOL HCI as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain NEBIVOLOL HCI and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a NEBIVOLOL HCI NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of NEBIVOLOL HCI suppliers with NDC on PharmaCompass.
NEBIVOLOL HCI Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of NEBIVOLOL HCI GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right NEBIVOLOL HCI GMP manufacturer or NEBIVOLOL HCI GMP API supplier for your needs.
A NEBIVOLOL HCI CoA (Certificate of Analysis) is a formal document that attests to NEBIVOLOL HCI's compliance with NEBIVOLOL HCI specifications and serves as a tool for batch-level quality control.
NEBIVOLOL HCI CoA mostly includes findings from lab analyses of a specific batch. For each NEBIVOLOL HCI CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
NEBIVOLOL HCI may be tested according to a variety of international standards, such as European Pharmacopoeia (NEBIVOLOL HCI EP), NEBIVOLOL HCI JP (Japanese Pharmacopeia) and the US Pharmacopoeia (NEBIVOLOL HCI USP).